Chemaphor Inc.

Chemaphor Inc.

September 10, 2008 09:00 ET

Chemaphor Appoints Dr. Paul Dick as Chief Executive Officer

OTTAWA, CANADA--(Marketwire - Sept. 10, 2008) - Chemaphor Inc. (TSX VENTURE:CFR), a biotechnology research and development company today announced the appointment of Dr. Paul Dick as Chief Executive Officer. Dr. Paul Dick holds a veterinary degree with advanced training in infectious diseases and immunology. He has held positions of increasing responsibility over nearly twenty years with two multinational pharmaceutical companies including Chief Operating Officer of Naturagen Health Solutions, within Elanco, a division of Eli Lilly and Company (NYSE:LLY). Dr. Dick has championed several leading product candidates, applying his expertise in product development, regulatory affairs, government relations, quality control and general management to maximize success.

Dr. Dick replaces Dr. Graham Burton as Chief Executive Officer. Dr. Burton will continue as President of Chemaphor Inc.

"On behalf of the Board of directors, I am pleased that Paul is joining our team" stated David Hankinson, Chairman of the Board of Chemaphor Inc. "We believe that the leadership, management and technical skill set that Paul brings to Chemaphor complements the capabilities of our senior management group and will help accelerate our progress to market."

Dr. Graham Burton, President of Chemaphor Inc., stated "We believe that Paul's technical capabilities, business acumen and dynamic style are exactly what are needed to help unlock the potential of Chemaphor's technology in the field of carotenoid oxidation products. Paul has world class knowledge, contacts and practical experience in the key focus areas for Chemaphor and we are very excited as to how far his drive, leadership and insight will take us. I look forward in continuing my role as President and complementing Paul in his role as CEO to reach the Company's objective of earning its first significant revenues from the OxBC platform and growing the company through acquisitions of new technologies."

Dr. Paul Dick stated, "I have long been interested in the potential of OxBC as a breakthrough natural health product. I have already had the pleasure of working, as a partner, with the Chemaphor team through Elanco. As difficult as it is to leave a position with a world class pharmaceutical company, I believe that in the case of Chemaphor, we have an optimal combination of an exciting best in class product, a market ready for the rapid adoption of such a product, and, an outstanding team of very talented and credible people which can deliver the results. I look forward to applying our collective skills to achieve success."

About Chemaphor

Chemaphor Inc. ( uses its core expertise in organic chemistry to develop premium products for the animal health, skin care cosmetics, pharmaceutical and specialty chemical markets. The Company's focus is on two proprietary products, a non pharmaceutical product OxBC and a lead cancer drug compound OCL-1. Chemaphor's goal is to fully exploit its proprietary platform of carotenoid oxidation compounds by finding recognized partners to commercialize its products in multiple, large markets.

Forward-looking statements

This news release contains forward-looking information. These statements relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management of Chemaphor Inc. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and Chemaphor Inc. does not assume any obligation to update or revise them to reflect new events or circumstances. (The TSX-Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.)

Contact Information